ALLOGRAFT VEIN PATENCY IN A CANINE MODEL - ADDITIVE EFFECTS OF CRYOPRESERVATION AND CYCLOSPORINE

被引:25
作者
AUGELLI, NV [1 ]
LUPINETTI, FM [1 ]
ELKHATIB, H [1 ]
SANOFSKY, SJ [1 ]
ROSSI, NP [1 ]
机构
[1] UNIV IOWA,COLL MED,DEPT SURG,DIV CARDIOTHORAC SURG,IOWA CITY,IA 52242
关键词
D O I
10.1097/00007890-199109000-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autogenous saphenous vein is the preferred conduit for many cardiovascular operations. Attempts to use allograft veins for arterial reconstruction have had poor results. To define circumstances under which allograft veins might prove to be acceptable vascular conduits, dogs underwent femoral artery bypass using reversed saphenous veins. Veins were transplanted fresh or after cryopreservation. Group I dogs received a fresh autograft to replace one femoral artery (group I F) and a cryopreserved (CP) autograft (group I C) to replace the other. Group II dogs received fresh allograft veins, and group III received CP allograft veins, neither group receiving additional treatment. Group IV received fresh allograft veins and Group V received CP allograft veins; both groups received cyclosporine 15 mg/kg. Animals were maintained until grafts occluded or until six months elapsed. Patency was observed in all group I F grafts throughout the observation period. Six-month patency rates in the other groups were: group I C, 9/10 (P = NS vs. group I F); group II, 0/10 (P < 0.01), group III, 0/10 (P < 0.01), group IV, 1/10 (P < 0.01), group V, 7/11 (P = NS). In a separate series of observations 10 cryopreserved allograft veins were implanted in 10 dogs that received CsA for 30 days. CsA was then discontinued. All of these grafts occluded within 30 days of discontinuing the CsA. Long-term patency of saphenous vein allografts was achieved only with the combination of cryopreservation and immunosuppression with continued CsA.
引用
收藏
页码:466 / 470
页数:5
相关论文
共 38 条
[21]  
OCHSNER JL, 1984, J VASC SURG, V1, P306
[22]  
OYER PE, 1983, TRANSPLANT P, V15, P2546
[23]   INDUCIBLE EXPRESSION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS AND THE IMMUNOGENICITY OF VASCULAR ENDOTHELIUM [J].
POBER, JS ;
COLLINS, T ;
GIMBRONE, MA ;
LIBBY, P ;
REISS, CS .
TRANSPLANTATION, 1986, 41 (02) :141-146
[24]   HEART-LUNG TRANSPLANTATION - SUCCESSFUL THERAPY FOR PATIENTS WITH PULMONARY VASCULAR-DISEASE [J].
REITZ, BA ;
WALLWORK, JL ;
HUNT, SA ;
PENNOCK, JL ;
BILLINGHAM, ME ;
OYER, PE ;
STINSON, EB ;
SHUMWAY, NE .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (10) :557-564
[25]  
RICOTTA JJ, 1980, ARCH SURG-CHICAGO, V115, P99
[26]  
SALAMAN J, 1988, TRANSPLANT P, V20, P117
[27]   IMMUNOSUPPRESSIVE TREATMENT OF AORTIC ALLOGRAFTS [J].
SCHMITZRIXEN, T ;
MEGERMAN, J ;
COLVIN, RB ;
WILLIAMS, AM ;
ABBOTT, WM .
JOURNAL OF VASCULAR SURGERY, 1988, 7 (01) :82-92
[28]  
SHOWALTER D, 1989, SURGERY, V106, P652
[29]   NEPHROTOXICITY OF CYCLOSPORIN-A AFTER ALLOGENEIC MARROW TRANSPLANTATION - GLOMERULAR THROMBOSES AND TUBULAR INJURY [J].
SHULMAN, H ;
STRIKER, G ;
DEEG, HJ ;
KENNEDY, M ;
STORB, R ;
THOMAS, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (23) :1392-1395
[30]   LIVER-TRANSPLANTATION WITH USE OF CYCLOSPORIN-A AND PREDNISONE [J].
STARZL, TE ;
KLINTMALM, GBG ;
PORTER, KA ;
IWATSUKI, S ;
SCHROTER, GPJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (05) :266-269